My Biocon Biologicsᵀᴹ provides FULPHILA® patient access support

A team of dedicated patient access specialists is available to answer calls and address concerns or questions regarding:

Coverage Coverage & claim

  • Verify appeal requirements
  • Track status and resolution of appeals

Coverage Alternate Coverage Identification

  • My Biocon Biologics can help identify other resources, such as state programs or third-party charitable foundations, that may be able to assist your patients

Patient Assistance Insurance coverage verification

  • Check patient insurance plan enrollment status

Benefit Investigation Benefit Investigation

  • Research patient-specific insurance coverage, coding, and billing requirements for FULPHILA and its administration
  • Verify patient cost-sharing requirements including deductible, co-pay, coinsurance, and out-of-pocket maximum, and amounts met to date
  • Determine payer access requirements (eg, specialty pharmacy, in-office dispensing, etc)
  • Prepare Summary of Benefits that documents all findings

Patient Assistance Patient Enrollment

Prior authorization Prior Authorization (PA) / Reauthorization Assistance & Tracking

  • Check PA requirements, submission details, and track status
  • Provide offices with payer-specific forms

Billing & Coding

  • Provide information about applicable coding for FULPHILA (pegfilgrastim-jmdb) and its administration.
  • Click here to access the Coding and Billing Guide for Fulphila.

Note: Coding information is provided for informational purposes only and the physician must determine the appropriate code for each patient and payer

Experienced and caring My Biocon Biologics patient access specialists are available
  • Patient support services and resources are available 24 hours a day, 7 days a week, via the My Biocon Biologics portal at
  1. Fulphila® (pegfilgrastim-jmdb) injection. Prescribing information. 2023. Biocon Biologics Inc. Cambridge, MA.
  2. U.S. Food and Drug Administration. Biosimilars. Available at:
    Accessed on: 10 August 2023.
  3. Vogel C, et al. J Clin Oncol. 2005;23:1178-1184.
  4. Waller, C.F., Ranganna, G.M., Pennella, E.J. et al. Ann Hematol. (2019) 98: 1217.

You are now leaving the Fulphila® website

You are now leaving this Biocon Biologics affiliate site. Biocon Biologics is not responsible for the content of the site you are about to visit.